946 related articles for article (PubMed ID: 27959701)
1. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI; Kutlar A; Kanter J; Liles D; Cancado R; Friedrisch J; Guthrie TH; Knight-Madden J; Alvarez OA; Gordeuk VR; Gualandro S; Colella MP; Smith WR; Rollins SA; Stocker JW; Rother RP
N Engl J Med; 2017 Feb; 376(5):429-439. PubMed ID: 27959701
[TBL] [Abstract][Full Text] [Related]
2. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
Kutlar A; Kanter J; Liles DK; Alvarez OA; Cançado RD; Friedrisch JR; Knight-Madden JM; Bruederle A; Shi M; Zhu Z; Ataga KI
Am J Hematol; 2019 Jan; 94(1):55-61. PubMed ID: 30295335
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):535-543. PubMed ID: 32350885
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Terrin ML; Moore RD; Dover GJ; Barton FB; Eckert SV; McMahon RP; Bonds DR
N Engl J Med; 1995 May; 332(20):1317-22. PubMed ID: 7715639
[TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease.
Delgado J; Voltz C; Stain M; Lapveteläinen T; Urach S; Lähteenvuo J; Penttilä K; Gisselbrecht C; Enzmann H; Pignatti F
Hemasphere; 2021 Jul; 5(7):e604. PubMed ID: 34235401
[TBL] [Abstract][Full Text] [Related]
7. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
9. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Biemond BJ; Tombak A; Kilinc Y; Al-Khabori M; Abboud M; Nafea M; Inati A; Wali Y; Kristensen J; Kowalski J; Donnelly E; Ohd J;
Lancet Haematol; 2021 May; 8(5):e334-e343. PubMed ID: 33894169
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar's healthcare perspective.
Adel AM; Abushanab D; Al-Badriyeh D; Hamad A; Alshurafa A; Yassin MA
SAGE Open Med; 2024; 12():20503121231224551. PubMed ID: 38711465
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report.
Afana MS; Abu-Tineh M; Alshurafa A; Yasin AK; Ahmed K; Abdulgayoom M; Yassin MA
Hematology; 2023 Dec; 28(1):2229115. PubMed ID: 37519115
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
Sy SKB; Tanaka C; Grosch K
Clin Pharmacokinet; 2023 Feb; 62(2):249-266. PubMed ID: 36529836
[TBL] [Abstract][Full Text] [Related]
14. Crizanlizumab: First Approval.
Blair HA
Drugs; 2020 Jan; 80(1):79-84. PubMed ID: 31933169
[TBL] [Abstract][Full Text] [Related]
15. Magnesium for treating sickle cell disease.
Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
[TBL] [Abstract][Full Text] [Related]
16. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA
Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
18. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
19. A critical evaluation of crizanlizumab for the treatment of sickle cell disease.
Karki NR; Saunders K; Kutlar A
Expert Rev Hematol; 2022 Jan; 15(1):5-13. PubMed ID: 34942078
[TBL] [Abstract][Full Text] [Related]
20. Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.
Stevens DL; Hix M; Gildon BL
J Pharm Technol; 2021 Aug; 37(4):209-215. PubMed ID: 34752581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
